Teva slips after launch of second generic Copaxone

As previously reported, Novartis (NVS) division Sandoz announced the FDA approval and U.S. launch of Glatopa 40 mg/mL. Glatopa 40 mg/mL is FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone and was developed under a collaboration agreement between Momenta Pharmaceuticals (MNTA) and Sandoz. Shares of Teva (TEVA), the maker of branded Copaxone, are down 59c, or 3%, to $18.68 in pre-market trading following the announcement.

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks